Exagen Inc. (NASDAQ:XGN) Short Interest Up 162.5% in March

Exagen Inc. (NASDAQ:XGN - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 46,200 shares, a growth of 162.5% from the March 15th total of 17,600 shares. Based on an average daily trading volume, of 135,600 shares, the short-interest ratio is currently 0.3 days. Approximately 0.5% of the company's stock are short sold.

Exagen Stock Up 0.4 %

Shares of XGN traded up $0.02 during midday trading on Friday, hitting $4.49. The company had a trading volume of 37,843 shares, compared to its average volume of 86,983. The company has a quick ratio of 4.05, a current ratio of 4.05 and a debt-to-equity ratio of 1.54. Exagen has a 52 week low of $1.32 and a 52 week high of $6.22. The company's 50 day moving average price is $3.85 and its 200 day moving average price is $3.78. The stock has a market cap of $80.36 million, a price-to-earnings ratio of -4.78 and a beta of 1.46.

Analysts Set New Price Targets

XGN has been the subject of a number of analyst reports. William Blair reissued an "outperform" rating on shares of Exagen in a research report on Wednesday, March 12th. Canaccord Genuity Group increased their price target on Exagen from $5.00 to $7.00 and gave the company a "buy" rating in a report on Friday, January 3rd. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $8.00 price objective on shares of Exagen in a report on Monday, January 13th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Corient Private Wealth LLC acquired a new stake in shares of Exagen during the 4th quarter valued at approximately $45,000. Virtu Financial LLC bought a new stake in Exagen during the fourth quarter valued at $46,000. Marshall Wace LLP acquired a new stake in shares of Exagen during the fourth quarter worth $66,000. Northern Trust Corp lifted its position in shares of Exagen by 16.7% in the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company's stock worth $75,000 after buying an additional 2,630 shares during the last quarter. Finally, Palumbo Wealth Management LLC boosted its holdings in shares of Exagen by 13.5% in the 4th quarter. Palumbo Wealth Management LLC now owns 86,704 shares of the company's stock valued at $355,000 after buying an additional 10,340 shares during the period. Institutional investors own 75.25% of the company's stock.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).